Neuronetics (STIM) closed at $2.15 on November 6, 2026, down 11.5% from the previous close, on volume of 3,581,331 shares (30-day average 936,331).
Data as of November 6, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
BTIG Remains a Buy on Neuronetics (STIM)
TipRanks (Thu, 5-Nov 6:15 AM ET)
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 4-Nov 4:30 PM ET)
Neuronetics Rallies After Q3: Greenbrook Revenue Rose 20.1% and Operating Income Turned Positive
Market Chameleon (Wed, 4-Nov 6:51 AM ET)
Neuronetics Reports Strong Third-Quarter Results and Strategic Partnerships
TipRanks (Wed, 4-Nov 8:18 AM ET)
Neuronetics beats top-line and bottom-line estimates; updates FY26 outlook
Seeking Alpha News (Wed, 4-Nov 7:54 AM ET)
Neuronetics Reports Third Quarter 2026 Financial and Operating Results
Globe Newswire (Wed, 4-Nov 7:50 AM ET)
Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call
Globe Newswire (Wed, 21-Oct 8:30 AM ET)
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
Globe Newswire (Tue, 8-Sep 8:32 AM ET)
Neuronetics Reports Second Quarter 2026 Financial and Operating Results
Globe Newswire (Tue, 11-Aug 7:50 AM ET)
Neuronetics' Clinic Revenue Jumps 37% and Positive Cash Flow Caps a Year of Rapid Expansion
Market Chameleon (Wed, 11-Feb 5:34 AM ET)
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Neuronetics trades on the NASDAQ stock market under the symbol STIM.
As of November 9, 2026, STIM stock price climbed to $2.20 with 2,243,892 million shares trading.
STIM has a beta of 3.16, meaning it tends to be more sensitive to market movements. STIM has a correlation of 0.12 to the broad based SPY ETF.
STIM has a market cap of $167.63 million. This is considered a Micro Cap stock.
Last quarter Neuronetics reported $42 million in Revenue and -$.02 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.08.
In the last 3 years, STIM traded as high as $5.92 and as low as $.52.
The top ETF exchange traded funds that STIM belongs to (by Net Assets): VTI, PSIL, VXF, BUSM, IWC.
STIM has underperformed the market in the last year with a return of -12.7%, while the SPY ETF gained +13.7%. In the last 3 month period, STIM fell short of the market, returning -2.2%, while SPY returned -1.6%. However, in the most recent 2 weeks STIM has outperformed the stock market by returning +4.3%, while SPY returned -0.7%.
STIM support price is $2.03 and resistance is $2.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STIM shares will trade within this expected range on the day.